The times they are a-changin': new antibacterials for skin and skin structure infections.

about

Exploration of the structure-activity relationship of 1,2,4-oxadiazole antibiotics Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

P2860

Q36167152-8D18E1B3-3CBE-4285-8B91-88085428CE83 Q39042375-933310F3-9AAC-4D1E-9564-24E06C126F36

P2860

The times they are a-changin': new antibacterials for skin and skin structure infections.

Item

http://www.wikidata.org/entity/Q38438503

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The times they are a-changin': new antibacterials for skin and skin structure infections.

@en

type

Item

label

The times they are a-changin': new antibacterials for skin and skin structure infections.

@en

prefLabel

The times they are a-changin': new antibacterials for skin and skin structure infections.

@en

P1476

The times they are a-changin': new antibacterials for skin and skin structure infections.

@en

P2093

Ellie J C Goldstein

http://www.w3.org/2001/XMLSchema#string

Mai-Chi N Tran

http://www.w3.org/2001/XMLSchema#string

Snezana Naumovski

http://www.w3.org/2001/XMLSchema#string

P2860

Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines

Trends in US hospital admissions for skin and soft tissue infections

Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

P2888

s40257-015-0125-9

P304

137-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40257-015-0125-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275358210

http://www.w3.org/2001/XMLSchema#string

P6179

1012982220

http://www.w3.org/2001/XMLSchema#string

P698

25906205

http://www.w3.org/2001/XMLSchema#string

The times they are a-changin': new antibacterials for skin and skin structure infections.

about

P2860

P2860

The times they are a-changin': new antibacterials for skin and skin structure infections.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698